Latest Approvals News

Strickland Metals has lifted its Rogozna resource to 9.25 million ounces of gold equivalent, but the exploration company also reported a A$10.39 million FY2026 loss. The cash balance rose sharply after a A$55.11 million placement as the company prepares for studies, permitting and a leadership transition.

Charger Metals has reduced its FY2026 loss and secured $3.75 million from the sale of Bynoe, giving the lithium explorer more room to advance its Lake Johnston assets. The company’s Medcalf resource now stands at 10.6Mt, although further drilling and funding will be needed to test its economic potential.

Imagion Biosystems has secured central ethics approval for its US Phase 1b/2 trial of the MagSense HER2 imaging agent, removing a key requirement before recruitment can begin. Site activation is now underway, but no patient has yet been enrolled and the announcement provides no clinical data.

Emperor Energy has secured NOPSEMA approval for the Judith-2 appraisal well, removing a major regulatory barrier ahead of targeted drilling in April 2027. The well will test a 166 Bcf contingent gas resource and investigate deeper prospective sands, although commercial conversion remains unproven.

Atlas Arteria has warned that France may more than double the tax rate applied to eligible toll-road operators, with APRR’s 2025 TEILD bill already reaching €126.7 million. The proposed changes remain subject to parliamentary debate and could be softened before becoming law.

Mayne Pharma has settled patent litigation with Sun Pharma over IMVEXXY, establishing 21 October 2032 as the agreed potential generic entry date, subject to court approval. The settlement involves no upfront payment, while one further Paragraph IV dispute remains unresolved.

Paradigm Biopharmaceuticals has entered voluntary administration after its pivotal Phase 3 trial produced an interim efficacy result below the threshold required for continuation. The company’s securities will remain suspended while administrators assess its viability, liabilities and possible restructuring options.

Silver Mines has built a substantially larger economic case for Bowdens, but the project still needs NSW approval before its 93.5 million ounce reserve can become a mine. The company is now funding the next phase with a A$70 million placement while absorbing dilution and a major royalty buy-back.

Papyrus Australia has produced a second batch of TBS board samples, expanded pulp capacity in Adelaide and secured additional funding as it moves towards commercial supply. The progress comes with testing still incomplete and an estimated 4.87 months of funding available.

Larvotto Resources has extended high-grade antimony-gold-tungsten mineralisation at Clarks Gully about 100 metres beyond its 2025 resource model, with drilling also identifying several hanging-wall lodes. The results could support a larger resource and a potential underground feed source for Hillgrove, but assays, modelling and permitting work remain outstanding.

Accelerate Resources enters FY2027 with high-grade manganese targets at Woodie Woodie North and new gold zones at Balagundi, but a sharp annual loss and ongoing funding needs remain part of the story. The company plans maiden and follow-up drilling while seeking shareholder approval to rename itself Mango Metals.

Vectus Biosystems has secured a pre-IND Type B meeting with the FDA for its lead IPF drug candidate VB0004. The regulator’s written feedback, expected by mid-November, should clarify the next US development steps but does not yet authorise clinical trials.